



Teva Pharmaceutical Industries Ltd.

Line Of Business

Development, Production and Marketing of Medicines and Active Pharmaceutical Ingredients

Established

Founded in Israel in 1901 by three young pharmacists, Teva Pharmaceutical Industries Limited is a leading global pharmaceutical company, headquartered in Israel

exists in two dosage forms – 20 mg/ml for daily use, and the more recently launched 40 mg/ml for three times a week use; Azilect[®], for the treatment of Parkinson's disease; and Nuvigil[®], for the treatment of sleepiness associated with some sleep disorders. Teva's CNS portfolio also includes products for the treatment of pain in opioid-tolerant adult cancer patients, and muscle spasm relief in musculoskeletal conditions, and Adasuve[®] for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults.

Teva continues to invest in the development of non-opioid alternatives and abuse-deterrent opioids for the treatment of pain, and is further investing in creating treatments for migraine.



Respiratory: Teva delivers a range of medicines for asthma, chronic obstructive pulmonary disease ("COPD") and allergic rhinitis. Its portfolio is centered on optimizing respiratory therapies for patients through novel delivery systems and therapies that address unmet needs. Teva's respiratory products include: DuoResp Spiromax[®] for the treatment of asthma and COPD; ProAir[®] for the treatment or prevention of bronchospasm; QVAR[®]

for the treatment of asthma; and QNASL[®] Nasal Aerosol for the treatment of seasonal and perennial allergic rhinitis.

Women's Health: Teva markets a diverse portfolio of products that promote women's health. Its main products include Plan B One-Step[®], an emergency oral contraceptive, Quartette[™], an extended-regimen oral contraceptive; Seasonique[®], an extended-cycle oral contraceptive; and Paragard[®] an intrauterine device (IUD).

Oncology: Teva's oncology medicines are dedicated to improving the lives of people with cancer. Teva's oncology medicines include: Treanda[®], for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma and Synribo[®] for treatment of adult patients with chronic phase or accelerated phase chronic myeloid leukemia. Teva also markets several biologic medications which are often part of the treatment regimen for oncology patients. These include Tevagrastim[®], a biosimilar G-CSF used to reduce the risk of infections in oncology patients receiving chemotherapy; Granix[®], a short-acting G-CSF; and Lonquex[®], a novel long-acting G-CSF, indicated for the reduction of neutropenia.

Additional Offerings

Over The Counter Products: Teva has a global OTC business, primarily through its winning alliance with the Procter & Gamble company, which combines Teva's production capabilities and market reach with P&G's marketing expertise and expansive global platform.

Active Pharmaceutical Ingredients: Teva is one of the leading global manufacturers of active pharmaceutical ingredients, the essential raw materials of the drug manufacturing industry.

Financial & Trading Information

In 2013, Teva posted net revenues of \$20.3 billion. Teva's shares are traded on the New York Stock Exchange under the symbol "TEVA" and on the Tel Aviv Stock Exchange.



Contact:
www.tevapharm.com